BioLineRx is currently supporting investigator-initiated clinical trials and research collaborations for the treatment of pancreatic cancer. We encourage interested patients to speak with their healthcare team for more information on eligibility criteria for our active clinical trials.

Study Locations

Ongoing Motixafortide Clinical Trials

Investigator-initiated studies of motixafortide are currently enrolling patients in the following locations:

pancreatic cancer pin
Pancreatic Cancer
A map of Northeast USA with pins indicating BioLine clinical trial sites for sickle cell disease and pancreatic cancer.
STUDY TITLE

A Phase 2b Study with Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in Metastatic Treatment-naïve Pancreas Adenocarcinoma

CLINICAL PARTNER
Washington University in St. Louis logo
CONDITION

Pancreatic Cancer

STUDY LOCATION
New York, NY
Providence, RI
PHASE
Phase 2b
INFORMATION
NCT04543071

Research Areas of Focus for Motixafortide

BioLineRx’s commitment to patients in need is supported not only through our own clinical studies, but also by supporting independent, unsolicited research relating to motixafortide by external investigators, organizations, and institutions as part of our Investigator Initiated Studies (IIS) program. IIS proposals submitted to BioLineRx are reviewed by our scientific and medical committees for scientific merit as well as safety, legal, ethical, and budgetary considerations. Support by BioLineRx can take the form of funding, study drug, or a combination of both.

  • CXCR4 inhibition in immuno-oncology

To submit a proposal or for any further information, please email IIS@biolinerx.com.

White Curve shaped
White Curve shaped
Drugs on the way to the finish line

Learn about our growing pipeline of best-in-class therapeutics for patients with cancer and rare disease.

DISCOVER OUR PIPELINE